Related references
Note: Only part of the references are listed.CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2020)
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading
David N. Louis et al.
BRAIN PATHOLOGY (2020)
Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma
Nayan Lamba et al.
JAMA ONCOLOGY (2020)
Medulloblastomics revisited: biological and clinical insights from thousands of patients
Volker Hovestadt et al.
NATURE REVIEWS CANCER (2020)
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients
Craig Horbinski et al.
NEURO-ONCOLOGY (2019)
The Misclassification of Diffuse Gliomas: Rates and Outcomes
J. Bryan Iorgulescu et al.
CLINICAL CANCER RESEARCH (2019)
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
David W. Ellison et al.
ACTA NEUROPATHOLOGICA (2019)
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2018)
cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2018)
The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone
Carol Kruchko et al.
NEURO-ONCOLOGY (2018)
cIMPACT-NOW update 3: recommended diagnostic criteria for Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2018)
NCCN Guidelines® Insights Central Nervous System Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines
Louis Burt Nabors et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
The whole-genome landscape of medulloblastoma subtypes
Paul A. Northcott et al.
NATURE (2017)
Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients A Population-based Study
Mary E. Charlton et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)
Quinn T. Ostrom et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Kristian W. Pajtler et al.
CANCER CELL (2015)
Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011
Ryan L. Lym et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Nataliya Zhukova et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
Marcel Kool et al.
ACTA NEUROPATHOLOGICA (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
